CORRECTING and REPLACING -- Cempra to Present at Upcoming Investor Conferences
February 08, 2017 09:41 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cempra, Inc. (Nasdaq:CEMP), the Leerink Partners conference should be noted...
Cempra to Present at Upcoming Investor Conferences
February 08, 2017 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at J.P. Morgan Healthcare Conference
January 04, 2017 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) Begins Phase 3 Studies in Japan With Cempra’s Solithromycin
December 05, 2016 08:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study
September 29, 2016 16:15 ET
|
Cempra, Inc.
— Pre/post treatment biopsies confirm mean NAS reduction of 1.3 points after 90 days of treatment with solithromycin — — All six patients showed ALT reductions after 90 days of treatment with...
Cempra Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 01, 2016 16:05 ET
|
Cempra, Inc.
Current cash balance now expected to fund operations through 2017 Management to host webcast and conference call today at 4:30 p.m. EDTCHAPEL HILL, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- ...
Cempra Appoints John Bluth Executive Vice President, Investor Relations and Corporate Communications
August 01, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
June 28, 2016 07:00 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 28, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Host Analyst and Investor Day on June 23, 2016
June 16, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., June 16, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation)
May 25, 2016 16:30 ET
|
Melinta Therapeutics, Inc.
Solithromycin safety and efficacy further validated by Toyama (FUJIFILM) All efficacy outcome measures favored solithromycin Management to host Q&A webcast and conference call tomorrow at 8:00...